Pulmatrix (NASDAQ: PULM) Investor Presentation 9/5/2018
Pulmatrix Corporate Overview (2018.08) – final for website
Pulmatrix (NASDAQ: PULM) Investor Presentation
Healthcare
The $TRILLION Opportunity in CRISPR & DNA Sequencing Technologies
Cathie Wood, of ARK Genomic Revolution ETF(NYSE: ARKG) explains the multi-trillion dollar opportunity in the Genomics Revolution: CAR-T, CRISPR, and DNA Sequencing Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential! Thank you for […]
Healthcare
FDA Grants Rolling Review for CytoDyn’s (OTC: CYDY) Planned BLA for Investigational HIV Therapy Leronlimab (PRO 140)
VANCOUVER, Washington, March 04, 2019 — CytoDyn Inc. (otc.qb:CYDY), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the FDA has reviewed […]
Healthcare
CytoDyn (OTC: CYDY) Files Pivotal Trial Protocol for HIV Monotherapy with FDA
VANCOUVER, Washington, May 15, 2019 — After four years of monotherapy trials, data is now available to submit the long-anticipated pivotal trial for monotherapy to the FDA Trial will include 10 weeks of induction therapy […]